Abstract
During the past 20 years, the proteins of the “contact system”, namely high molecular weight kininogen (HK), kallikrein and Factor XII have been shown to have very little direct impact on hemostasis despite their initial description as initiators of the “intrinsic system”. In fact these proteins have rather anticoagulant and profibrinolytic properties. The focus of this review is to summarize the known antithrombotic properties of HK demonstrating its potential application for the novel therapeutic interventions against thromboembolic complications. In particular, HK can inhibit platelet aggregation, as (i) its domain 5 interferes with ligand binding of αIIbβ3-integrins, (ii) its domain 3 blocks thrombin-dependent platelet aggregation by interfering with thrombin binding to the glycoprotein Ib-IX-V complex on platelets, (iii) bradykinin, which is derived upon cleavage of HK, blocks thrombin-induced platelet aggregation, and (iv) HK domain 2 can inhibit the function of platelet calpain. Moreover, HK may have profibrinolytic actions as it can (i) inhibit plasminogen activator inhibitor-1 function and (ii) potentiate prourokinase activation with subsequent pericellular plasmin formation. Indeed, patients lacking circulating HK are at increased risk for thrombosis, and a prothrombotic phenotype was reported for kininogendeficient rats. All these observations render kininogen antithrombotic, rather than prothrombotic, and the ongoing research aims to develop novel kininogen-related antithrombotic therapies.
Keywords: Antithrombotic Molecule, profibrinolytic actions, bradykinin, thrombosis, prothrombotic phenotype
Current Vascular Pharmacology
Title: Potential Pharmacological Applications of the Antithrombotic Molecule High Molecular Weight Kininogen
Volume: 1 Issue: 1
Author(s): Triantafyllos Chavakis and Klaus T. Preissner
Affiliation:
Keywords: Antithrombotic Molecule, profibrinolytic actions, bradykinin, thrombosis, prothrombotic phenotype
Abstract: During the past 20 years, the proteins of the “contact system”, namely high molecular weight kininogen (HK), kallikrein and Factor XII have been shown to have very little direct impact on hemostasis despite their initial description as initiators of the “intrinsic system”. In fact these proteins have rather anticoagulant and profibrinolytic properties. The focus of this review is to summarize the known antithrombotic properties of HK demonstrating its potential application for the novel therapeutic interventions against thromboembolic complications. In particular, HK can inhibit platelet aggregation, as (i) its domain 5 interferes with ligand binding of αIIbβ3-integrins, (ii) its domain 3 blocks thrombin-dependent platelet aggregation by interfering with thrombin binding to the glycoprotein Ib-IX-V complex on platelets, (iii) bradykinin, which is derived upon cleavage of HK, blocks thrombin-induced platelet aggregation, and (iv) HK domain 2 can inhibit the function of platelet calpain. Moreover, HK may have profibrinolytic actions as it can (i) inhibit plasminogen activator inhibitor-1 function and (ii) potentiate prourokinase activation with subsequent pericellular plasmin formation. Indeed, patients lacking circulating HK are at increased risk for thrombosis, and a prothrombotic phenotype was reported for kininogendeficient rats. All these observations render kininogen antithrombotic, rather than prothrombotic, and the ongoing research aims to develop novel kininogen-related antithrombotic therapies.
Export Options
About this article
Cite this article as:
Chavakis Triantafyllos and Preissner T. Klaus, Potential Pharmacological Applications of the Antithrombotic Molecule High Molecular Weight Kininogen, Current Vascular Pharmacology 2003; 1 (1) . https://dx.doi.org/10.2174/1570161033386790
DOI https://dx.doi.org/10.2174/1570161033386790 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Key Advances in MIP-based Sensors Applied for Cancer and Cardiovascular
Biomarkers Detection
Current Topics in Medicinal Chemistry Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Awareness and Perception of Thromboembolism and Thromboprophylaxis among Hospitalized Patients in Jordan
Current Clinical Pharmacology Clinical Characteristics of Inpatients with Coronavirus Disease 2019 and Acute Ischemic Stroke: From Epidemiology to Outcomes
Current Neurovascular Research Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome
Current Medicinal Chemistry Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Simultaneous Genotyping of Four Single Nucleotide Polymorphisms Associated with Risk Factors of Hemostasis Disorders
Combinatorial Chemistry & High Throughput Screening Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Clinical Applications of Transcranial Doppler Sonography
Reviews on Recent Clinical Trials Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Pulmonary Embolism and Pregnancy
Current Women`s Health Reviews The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Current Drug Targets The Successful Treatment of Pulmonary Embolism as a Complication after Uterine Fibroid Embolization (Case Report)
Current Women`s Health Reviews Acute Coronary Syndromes as Auto-Inflammatory Disorders
Current Pharmaceutical Design Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology